| Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice D Foti, E Chiefari, M Fedele, R Iuliano, L Brunetti, F Paonessa, ... Nature medicine 11 (7), 765-773, 2005 | 239 | 2005 |
| Human diabetes associated with defects in nuclear regulatory proteins for the insulin receptor gene. A Brunetti, L Brunetti, D Foti, D Accili, ID Goldfine The Journal of clinical investigation 97 (1), 258-262, 1996 | 43 | 1996 |
| Natural compounds for the prevention and treatment of cardiovascular and neurodegenerative diseases R Leuci, L Brunetti, V Poliseno, A Laghezza, F Loiodice, P Tortorella, ... Foods 10 (1), 29, 2020 | 35 | 2020 |
| New Approaches to Cancer Therapy: Combining Fatty Acid Amide Hydrolase (FAAH) Inhibition with Peroxisome Proliferator-Activated Receptors (PPARs) Activation: Miniperspective L Brunetti, F Loiodice, L Piemontese, P Tortorella, A Laghezza Journal of Medicinal Chemistry 62 (24), 10995-11003, 2019 | 29 | 2019 |
| Importance of biometals as targets in medicinal chemistry: An overview about the role of Zinc (II) chelating agents R Leuci, L Brunetti, A Laghezza, F Loiodice, P Tortorella, L Piemontese Applied Sciences 10 (12), 4118, 2020 | 28 | 2020 |
| Deep eutectic solvents as effective reaction media for the synthesis of 2-hydroxyphenylbenzimidazole-based scaffolds en route to donepezil-like compounds L Piemontese, R Sergio, F Rinaldo, L Brunetti, FM Perna, MA Santos, ... Molecules 25 (3), 574, 2020 | 27 | 2020 |
| Derivatives of tenuazonic acid as potential new multi-target anti-Alzheimer’s disease agents V Poliseno, S Chaves, L Brunetti, F Loiodice, A Carrieri, A Laghezza, ... Biomolecules 11 (1), 111, 2021 | 22 | 2021 |
| Structure-based design of novel donepezil-like hybrids for a multi-target approach to the therapy of Alzheimer's disease L Brunetti, R Leuci, A Carrieri, M Catto, S Occhineri, G Vinci, ... European Journal of Medicinal Chemistry 237, 114358, 2022 | 20 | 2022 |
| Combining fatty acid amide hydrolase (FAAH) inhibition with peroxisome proliferator-activated receptor (PPAR) activation: A new potential multi-target therapeutic strategy for … L Brunetti, A Laghezza, F Loiodice, P Tortorella, L Piemontese Neural Regeneration Research 15 (1), 67-68, 2020 | 17 | 2020 |
| Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer A Cortellini, A D'Alessio, S Cleary, S Buti, M Bersanelli, P Bordi, G Tonini, ... Clinical Cancer Research 29 (14), 2714-2724, 2023 | 15 | 2023 |
| Food industry byproducts as starting material for innovative, green feed formulation: a sustainable alternative for poultry feeding L Brunetti, R Leuci, MA Colonna, R Carrieri, FE Celentano, G Bozzo, ... Molecules 27 (15), 4735, 2022 | 15 | 2022 |
| Novel rivastigmine derivatives as promising multi-target compounds for potential treatment of Alzheimer’s disease D Vicente-Zurdo, N Rosales-Conrado, ME León-González, L Brunetti, ... Biomedicines 10 (7), 1510, 2022 | 15 | 2022 |
| Immunotherapy for metastatic non-small cell lung cancer: therapeutic advances and biomarkers M Russano, G La Cava, A Cortellini, F Citarella, A Galletti, GR Di Fazio, ... Current Oncology 30 (2), 2366-2387, 2023 | 10 | 2023 |
| Novel phenothiazine/donepezil-like hybrids endowed with antioxidant activity for a multi-target approach to the therapy of Alzheimer’s disease A Carocci, A Barbarossa, R Leuci, A Carrieri, L Brunetti, A Laghezza, ... Antioxidants 11 (9), 1631, 2022 | 10 | 2022 |
| A new series of aryloxyacetic acids endowed with multi-target activity towards peroxisome proliferator-activated receptors (PPARs), fatty acid amide hydrolase (FAAH), and … R Leuci, L Brunetti, A Laghezza, L Piemontese, A Carrieri, L Pisani, ... Molecules 27 (3), 958, 2022 | 10 | 2022 |
| Beyond the canonical endocannabinoid system. A screening of PPAR ligands as FAAH inhibitors L Brunetti, A Carrieri, L Piemontese, P Tortorella, F Loiodice, A Laghezza International Journal of Molecular Sciences 21 (19), 7026, 2020 | 9 | 2020 |
| A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity S Sblano, C Cerchia, A Laghezza, L Piemontese, L Brunetti, R Leuci, ... European Journal of Medicinal Chemistry 235, 114240, 2022 | 7 | 2022 |
| Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours C Celsa, G Cabibbo, CAM Fulgenzi, B Scheiner, A D’Alessio, GF Manfredi, ... Journal of Hepatology 80 (3), 431-442, 2024 | 6 | 2024 |
| Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty … F Intranuovo, L Brunetti, P DelRe, GF Mangiatordi, A Stefanachi, ... Journal of Medicinal Chemistry 66 (1), 235-250, 2022 | 5 | 2022 |
| Impact of neoadjuvant immune checkpoint inhibitors on surgery and perioperative complications in patients with non-small cell lung cancer: A systematic review. K Takada, S Takamori, L Brunetti, P Crucitti, A Cortellini Clinical Lung Cancer, 2023 | 4 | 2023 |
